The world of celiac disease research changes and evolves each and every day. Beyond Celiac keeps the community up-to-date on research in many ways, including our Research News Feed and the Research Opt-In.
In IBS patients, celiac disease diagnosis may be being missed in some cases, while in others the gluten-free diet may not be necessary, according to two new studies.
A Phase 2 clinical trial is testing a potential treatment, Amlitelimab, for celiac disease. Amlitelimab is a monoclonal antibody that is proposed to work in celiac disease by interrupting the immune response that occurs.
A new test developed by researchers in Australia has shown promising results in detecting a response to gluten in blood even when someone is on a gluten-free diet. Additionally, the test has the potential to eliminate the need for a biopsy to definitively diagnose celiac disease.
Breastfeeding in early infancy, the amount of gluten a baby consumes daily, as well as nationality, sex and birth order are environmental factors that influence whether at-risk children go on to develop celiac disease.
In celiac disease, changes in the gut that persist even on a gluten-free diet may lead to an immune “scar” that could be the cause of ongoing symptoms, new research funded by Beyond Celiac has found.
A potential celiac disease vaccine could one day be a reality. Whenever new information is available we update our Research News and our Celiac Disease Vaccine page.
Researchers around the world are working to develop new treatments for celiac disease. As a person affected by celiac disease, you can play an important role in advancing research by participating in clinical trials. View our Clinical Trials Infographic to learn how clinical trials tie into to drug development process.
Additionally, Beyond Celiac has been directly involved with assisting a number of clinical studies in all phases. With the largest celiac disease social community, a robust email and research database and a website that receives over 2 million visits a year, we are uniquely qualified to help your clinical trial recruit qualified candidates. Learn about our patient recruitment offerings.
Our Chief Scientific Officers lead the development and implementation of a transformational patient-centered research agenda focused on accelerating solutions toward new pharmaceutical treatments and a cure for celiac disease.
Our Chief Scientist and Strategy Officer develops our research and funding priorities to impact patients in areas including clinical decision-making about disease management, treatment, and eventually a cure.
Learn more about our Medical Advisory Council and Scientific Advisory Board.
Opt-in to stay up-to-date on the latest news.
Yes, I want to advance research No, I'd prefer not to